TIL - NASDAQ
Instil Bio, Inc.
$8.10
-0.84%Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
At a Glance
Live SnapshotInstil Bio, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Instil Bio, Inc. Balance Sheet
TIL • NASDAQ
| Instil Bio, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
6.6M | 8.8M | 9.2M | 43.7M | 37.6M | 241.7M | 8.9M | |
69.5M | 104.5M | 141.2M | 217.2M | 416.5M | 0.0 | 0.0 | |
76.1M | 113.3M | 150.4M | 260.9M | 454.1M | 241.7M | 8.9M | |
848K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
848K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 9.3M | 8.9M | 0.0 | 9.9M | 4.4M | 334K | |
114.5M | 1.8M | 1.5M | 8.5M | 0.0 | 0.0 | 57K | |
191.4M | 124.5M | 160.8M | 269.4M | 464M | 246.1M | 9.3M | |
NON-CURRENT ASSETS | |||||||
364K | 130.3M | 141.1M | 209.3M | 122M | 55.3M | 190K | |
0.0 | 0.0 | 0.0 | 0.0 | 5.7M | 5.7M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 10.1M | 10.1M | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 15.8M | 15.8M | 0.0 | |
0.0 | 0.0 | 23.2M | 0.0 | 0.0 | 0.0 | 0.0 | |
11.7M | 8.8M | 639K | 3.4M | 8.1M | 1.7M | 0.0 | |
12.1M | 139.1M | 164.9M | 212.8M | 146M | 72.9M | 190K | |
203.5M | 263.6M | 325.6M | 482.1M | 610M | 319M | 9.5M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
779K | 659K | 1.2M | 2.4M | 6.1M | 3.5M | 979K | |
779K | 659K | 1.2M | 2.4M | 5.6M | 3.5M | 979K | |
0.0 | 0.0 | 0.0 | 0.0 | 524K | 0.0 | 0.0 | |
0.0 | 3.5M | 6.4M | 23.8M | 21.6M | 7.2M | 185K | |
372K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 1.7M | 1.8M | 2.4M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 524K | 0.0 | 0.0 | |
3.7M | 2.1M | 1.2M | 4.2M | 13.7M | 2.6M | 256K | |
4.8M | 7.9M | 10.6M | 32.8M | 41.4M | 13.3M | 1.4M | |
NON-CURRENT LIABILITIES | |||||||
84.8M | 84.2M | 81.4M | 72.4M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 2.4M | 0.0 | 0.0 | |
8K | 1M | 4.9M | 8.2M | 11M | 13.4M | 14.9M | |
84.8M | 86.2M | 89.2M | 85.7M | 13.4M | 13.4M | 14.9M | |
0.0 | 2.7M | 4.6M | 7.6M | 0.0 | 0.0 | 0.0 | |
89.7M | 94.1M | 99.8M | 118.5M | 54.8M | 26.6M | 16.4M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 332M | 14.9M | |
840.9M | 824.8M | 807.2M | 789M | 757M | 5.6M | 293K | |
-726.5M | -655.1M | -581M | -424.9M | -201.7M | -44.9M | -7.2M | |
-583K | -228K | -348K | -493K | -87K | -283K | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -14.9M | |
113.9M | 169.4M | 225.8M | 363.6M | 555.2M | 292.4M | -6.9M | |
113.9M | 169.4M | 225.8M | 363.6M | 555.2M | 292.4M | -6.9M | |
SUMMARY | |||||||
203.5M | 263.6M | 325.6M | 482.1M | 610M | 319M | 9.5M | |
69.5M | 104.5M | 164.3M | 217.2M | 416.5M | 0.0 | 0.0 | |
85.2M | 86.9M | 86.1M | 79.9M | 0.0 | 0.0 | 0.0 | |
78.5M | 78.1M | 76.9M | 36.2M | -37.6M | -241.7M | -8.9M | |
6,750,698 | 6,750,698 | 6,750,698 | 6,750,698 | 6,750,698 | 6,750,698 | 6,750,698 |
SEC Filings
TIL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 03, 2026 | April 01, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 05, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 13, 2025 | August 13, 2025 | 2025 |
Related Guides
Continue your TIL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.